Investment Pharmaceuticals

Wed, 09/23/2009 - 16:53

Tasly Pharma to increase investment in Shanghui Investment by $42 mln

Shanghai. September 23. INTERFAX-CHINA - Leading traditional Chinese medicine manufacturer Tianjin Tasly Pharmaceutical Co. Ltd. will inject nearly RMB 284.80 million ($41.70 million) into Tianjin Shanghui Investment (Holding) Co. Ltd., it announced on Sept. 23.

This article is only accessible to Interfax subscribers. To gain access to this article, as well similar in-depth articles and industry-specific content, please contact our sales staff by telephone (+852 2537 2262) .

Start free trial NOW